Johnson & Johnson's prostate cancer drug Erleada, reportedly used alongside standard home-blocking therapy before and after ...

Please provide your email address to receive an email when new articles are posted on . Adding apalutamide to ADT before and ...

Detailed results from pivotal TALAPRO-3 study presented at ASCO 2026 and published in The New England Journal of Medicine ...

Prostate cancer specialists oppose plans to restrict screening to only a few thousand men, research has shown.

Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We ...

The majority of men in the UK will not be offered prostate cancer screening following a final recommendation from a committee ...

With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. For patients with high-risk localized or locally advanced ...

A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

A breakthrough in treating an aggressive form of prostate cancer could boost survival rates, according to new research.

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris ...

Research found that the weight-loss medications may reduce the spread of several obesity-related cancers, including lung, ...

The breakthrough at Columbia University lays the groundwork for future clinical studies aimed at developing new treatments.